从novobiocin类似物库中识别出的hsp90抑制剂
Xiao Ming Yu1, Gang Shen, Len Neckers
1Department of Medicinal Chemistry and The Center for Protein Structure and Function, The University of Kansas, 1251 Wescoe Hall Drive, Malott 4070, Lawrence, Kansas 66045-7582, USA.
Journal of the American Chemical Society
|September 15, 2005
概括
合成了诺沃生素衍生物来改善Hsp90的抑制. 衍生品A4有效降解了促进癌症的Hsp90客户端蛋白,显示了癌症治疗的潜力.
科学领域:
- 分子生物学分子生物学
- 在瘤学瘤学.
- 药物发现 药物发现 药物发现
背景情况:
- 热冲击蛋白90 (Hsp90) 对癌细胞生长和生存至关重要.
- 诺沃生素抑制Hsp90,但功效较低,限制了其治疗发展.
- 开发强大的Hsp90抑制剂是癌症研究的一个关键策略.
研究的目的:
- 为了合成和评估新型诺波素类似物作为潜在的Hsp90抑制剂.
- 为了识别具有针对Hsp90.0.改善抑制活性的衍生品.
- 评估这些衍生品在癌细胞中降解Hsp90客户端蛋白的有效性.
主要方法:
- 合成了 20 种新生物衍生物的并行库.
- 生物活性是使用西部斑分析来评估的.
- 在乳腺癌和前列腺癌细胞系中评估了Hsp90客户端蛋白 (AKT,Her2,Hif-1alpha,雄激素受体) 的降解.
主要成果:
- 衍生品A4在1 muM度下显示出强大的Hsp90抑制.
- A4诱导多个Hsp90客户端蛋白质的降解,这对癌症进展至关重要.
- 在乳腺癌和前列腺癌细胞系中观察到显著的退化.
结论:
- 新生物素类似物A4是一种强大的Hsp90.0抑制剂.
- A4有效地向关键的Hsp90客户端蛋白,为乳腺癌和前列腺癌提供了有前途的治疗策略.
- 对A4的进一步开发需要对癌症治疗进行研究.
相关概念视频
Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Inhibitors of Bacterial DNA Synthesis
Bacterial pathogens depend on precise and efficient DNA replication to sustain infection. Two type II topoisomerases—DNA gyrase and topoisomerase IV—are critical to this process, as they resolve DNA supercoiling and unlink chromosomes during replication. Fluoroquinolones, synthetic derivatives of quinolones, exploit this mechanism by stabilizing the transient DNA–enzyme cleavage complex, preventing strand religation, and causing lethal double-strand breaks. These antibiotics are selectively...
Antiviral Nucleoside Inhibitors
Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...


